DOWNSTREAM PROCESSING FEATURED ARTICLES
Researchers at the National Institutes of Health have discovered a genetic mutation that appears to increase production of red blood cells in tumors.
-
Theratechnologies Secures US Patent For Its Novel Peptide TH1173
Theratechnologies Inc. (TSX:TH)(NASDAQ:THER) today reported that the US Patent and Trademark Office (USPTO) has granted a patent (US Patent No. 8,361,964) for its second generation growth-hormone releasing factor (GRF) peptide, TH1173, providing for patent protection beyond 2030.
-
Research Breakthrough Selectively Represses The Immune System
In a mouse model of multiple sclerosis (MS), researchers funded by the National Institutes of Health have developed innovative technology to selectively inhibit the part of the immune system responsible for attacking myelin -- the insulating material that encases nerve fibers and facilitates electrical communication between brain cells.
-
Identified 115 Proteins That Would Allow Designing New Generation Anti-Cancer Drugs
Researchers from the Research Programme on Biomedical Informatics (GRIB) from the IMIM (Hospital del Mar Research Institute) and the Pompeu Fabra University (UPF) have identified 115 proteins in silico (via computer simulation) that could be highly relevant to treat colon-rectal cancer, since they would make it possible to define the strategy to design new generation anti-cancer drugs.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
Selecting The Optimal Resins For The Process Purification Of Native And Recombinant Proteins
Native and recombinant proteins are used in a variety of applications ranging from drug discovery to target validation to high-throughput screening. Due to this, large-scale protein production and purification have become major necessities in industrial settings.
-
Removal Of Host Cell Proteins During Monoclonal Antibody Purification
Protein A chromatography is a widely used and highly successful method of purifying recombinant monoclonal antibodies. However, since Protein A has high affinity for antibodies, harsh conditions such as low pH are often required to elute monoclonal antibodies from Protein A affinity columns. By 3M Purification Inc
-
Improving DNA Removal from Bioprocess Purification Processes
Many new biological drug products produced using recombinant DNA technology, such as monoclonal antibodies, are produced in cell culture. Because therapeutic proteins such as monoclonal antibodies are produced in cell culture, impurities can result from the host cells, or cell substrates. By 3M Purification Inc.
-
Automated Bioluminescent ADCC Reporter Bioassay Using Bioengineered Jurkat Cells
Pharmaceutical companies are increasingly exploring new biologic and biosimilar products, and thus increasing monoclonal antibody (mAb) immunotherapeutic research. By Tracy Worzella, Promega Corporation and Brad Larson, Applications Department, BioTek Instruments, Inc.
-
Automation Of A Homogeneous Proximity Assay For Detection Of Residual Protein A In Biological Therapeutics
Protein A is used in affinity chromatography for therapeutic antibody purification and has been shown to leach from columns during purification of antibodies resulting in contamination. Residual Protein A in therapeutic drugs could elicit mitogenic or immunological reactions in patients.
-
Chromatography Column Protection With 3M Purification LifeASSURE™ PLA Series Membrane Filters Protective, or guard, filters are often used in chromatography column purification steps to protect the column media from contaminants in the various fluids that come in contact with the column.